|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TECHNOLOGY DEVELOPMENT |
a Institute of Hematology and Medical Oncology "L. e A. Seràgnoli" and Stem Cells Research Center, S. Orsola-Malpighi Hospital, Bologna, Italy;
b Molecular and Transplantation Pathology Laboratory "Felice Addarii" and
c Department of Surgery and Transplant, Section of Ophthalmology, University of Bologna, Bologna, Italy;
d Immunotherapy and Gene Therapy Unit, National Cancer Center, Milano, Italy
Key Words. Nucleofection • Mesenchymal stem cells • Interleukin-12 • Gene therapy
Correspondence: Michela Aluigi, Ph.D., Institute of Hematology and Medical Oncology "L. e A. Seràgnoli," Via Massarenti, 9, 40137 Bologna, Italy. Telephone: 39-051-6363680; Fax: 39-051-6364037; e-mail: maluigi{at}biocfarm.unibo.it
Viral-based techniques are the most efficient systems to deliver DNA into stem cells because they show high gene transduction and transgene expression in many cellular models. However, the use of viral vectors has several disadvantages mainly involving safety risks. Conversely, nonviral methods are rather inefficient for most primary cells. The Nucleofector technology, a new nonviral electroporation-based gene transfer technique, has proved to be an efficient tool for transfecting hard-to-transfect cell lines and primary cells. However, little is known about the capacity of this technique to transfect adult stem cells. In this study, we applied the Nucleofector technology to engineer human bone marrow derived mesenchymal stem cells (hMSCs). Using a green fluorescent protein reporter vector, we demonstrated a high transgene expression level using U-23 and C-17 pulsing programs: 73.7% ± 2.9% and 42.5% ± 3.4%, respectively. Cell recoveries and viabilities were 38.7% ± 2.9%, 44.5% ± 3.9% and 91.4% ± 1.3%, 94.31% ± 0.9% for U-23 and C-17, respectively. Overall, the transfection efficiencies were 27.4% ± 2.9% (U-23) and 16.6% ± 1.4% (C-17) compared with 3.6% ± 2.4% and 5.4% ± 3.4% of other nonviral transfection systems, such as FUGENE6 and DOTAP, respectively (p < .005 for all comparisons). Nucleofection did not affect the immunophenotype of hM-SCs, their normal differentiation potential, or ability to inhibit T-cell alloreactivity. Moreover, the interleukin-12 gene could be successfully transfected into hMSCs, and the immunomodulatory cytokine was produced in great amount for at least 3 weeks without impairment of its biological activity. In conclusion, nucleofection is an efficient nonviral transfection technique for hMSCs, which then may be used as cellular vehicles for the delivery of biological agents.
This article has been cited by other articles:
![]() |
P. A. Walker, S. K. Shah, M. T. Harting, and C. S. Cox Jr Progenitor cell therapies for traumatic brain injury: barriers and opportunities in translation Dis. Model. Mech., January 1, 2009; 2(1-2): 23 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Carofino and J. R. Lieberman Gene Therapy Applications for Fracture-Healing J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 99 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bartels, A. T. Schweda, U. Dreikhausen, R. Frank, K. Resch, W. Beil, and M. Nourbakhsh Peptide-Mediated Disruption of NF{kappa}B/NRF Interaction Inhibits IL-8 Gene Activation by IL-1 or Helicobacter pylori J. Immunol., December 1, 2007; 179(11): 7605 - 7613. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Baksh, R. Yao, and R. S. Tuan Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow Stem Cells, June 1, 2007; 25(6): 1384 - 1392. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Curti, S. Pandolfi, B. Valzasina, M. Aluigi, A. Isidori, E. Ferri, V. Salvestrini, G. Bonanno, S. Rutella, I. Durelli, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells Blood, April 1, 2007; 109(7): 2871 - 2877. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-E. Zaragosi, N. Billon, G. Ailhaud, and C. Dani Nucleofection Is a Valuable Transfection Method for Transient and Stable Transgene Expression in Adipose Tissue-Derived Stem Cells Stem Cells, March 1, 2007; 25(3): 790 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Cesnulevicius, M. Timmer, M. Wesemann, T. Thomas, T. Barkhausen, and C. Grothe Nucleofection Is the Most Efficient Nonviral Transfection Method for Neuronal Stem Cells Derived from Ventral Mesencephali with No Changes in Cell Composition or Dopaminergic Fate Stem Cells, December 1, 2006; 24(12): 2776 - 2791. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |